The Proportion of Lymphocytic Inflammation with CD123-positive Cells in Lupus Erythematous Profundus Predict a Clinical Response to Treatment
DOI:
https://doi.org/10.2340/00015555-1777Keywords:
lupus erythematosus profundus, plasmacytoid dendritic cells, CD123, CD303.Abstract
Lupus erythematosus profundus is a rare inflammatory disorder of subcutaneous fat in patients with lupus ery-thematosus. Previous reports suggested that plasmacytoid dendritic cells, which expressed CD123 and CD303 antigens, play a central proinflammatory role in the patho-genesis of lupus erythematosus. To find the factors that determine the response to treatment, we analysed 23 skin specimens from the patients with lupus erythematosus profundus. The patients with considerable lymphocytic inflammation with high percentages of CD123+ cells in dermis and subcutaneous fat significantly responded to the systemic corticosteroid therapies. On the other hand, the patients with minor lymphocytic inflammation with low percentages of CD123+ cells showed poor response to treatments. The mean percentage of CD123+ cells in patients who showed good response to therapy was significantly higher than those that showed poor response (p=0.027). These results suggest that the clinical response to treatment of lupus erythematosus profundus could be predicted from the histological features.Downloads
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Azusa Miyashita, Satoshi Fukushima, Takamitsu Makino, Yuichiro Yoshino, Junji Yamashita, Noritoshi Honda, Jun Aoi, Asako Ichihara, Masatoshi Jinnin, Yuji Inoue, Hironobu Ihn
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.